Trial reportAmerican journal of ophthalmology2016
Effects of Hormone Therapy on Intraocular Pressure: The Women's Health Initiative-Sight Exam Study.
Trial report in American journal of ophthalmology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- The Association of Female Reproductive Factors with Glaucoma and Related Traits: A Systematic Review.Ophthalmology. GlaucomaPooled it
- Trial
- Racial Differences in the Effects of Hormone Therapy on Incident Open-Angle Glaucoma in a Randomized Trial.American journal of ophthalmology · 2018Trial
- Article
- Influence of Ocular and Systemic Variables on Intraocular Pressure Change Following Phacoemulsification in Non-Glaucomatous Eyes.Journal of ophthalmic & vision research · 2025Article
- Steroid hormones in fish, caution for present and future: A review.Toxicology reports · 2024Review
- Myopic shift in female mice after ovariectomy.Scientific reports · 2024Article
- Association of Age of Menopause and Glaucoma Diagnosis in Female Veterans.Investigative ophthalmology & visual science · 2024Article
- Postmenopausal Hormone Therapy Was Associated With Later Age of Onset Among Glaucoma Cases.Investigative ophthalmology & visual science · 2024Article
- Evidence for Menopause as a Sex-Specific Risk Factor for Glaucoma.Cellular and molecular neurobiology · 2023Review
- Red blood cell fatty acids and age-related macular degeneration in postmenopausal women.European journal of nutrition · 2022Article
- The vital role for nitric oxide in intraocular pressure homeostasis.Progress in retinal and eye research · 2021Review
- Association Between Sex Hormones and Visual Field Progression in Women With Primary Open Angle Glaucoma: A Cross-Sectional and Prospective Cohort Study.Frontiers in aging neuroscience · 2021Article
- The Role of Chromosome X in Intraocular Pressure Variation and Sex-Specific Effects.Investigative ophthalmology & visual science · 2020Article
- Age and Menopause Effects on Ocular Compliance and Aqueous Outflow.Investigative ophthalmology & visual science · 2020Article
- Interaction between postmenopausal hormone therapy and diabetes on cataract.Menopause (New York, N.Y.) · 2020Article
- Update on the genetics of primary open-angle glaucoma.Experimental eye research · 2019Review
- Sex hormone levels and risk of primary open-angle glaucoma in postmenopausal women.Menopause (New York, N.Y.) · 2018Article
- Impact of aromatase absence on murine intraocular pressure and retinal ganglion cells.Scientific reports · 2018Article
- Testosterone Pathway Genetic Polymorphisms in Relation to Primary Open-Angle Glaucoma: An Analysis in Two Large Datasets.Investigative ophthalmology & visual science · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
purposePrevious studies suggest that hormone therapy favorably affects intraocular pressure (IOP). Here, we examined the association between hormone therapy use and IOP in the context of a large randomized trial.
designSecondary data analysis from a randomized controlled trial.
methodsWe used data from the Women's Health Initiative-Sight Exam (WHISE). Women with prior hysterectomy received oral conjugated equine estrogen (0.625 mg/day) or placebo. Women with a uterus received estrogen plus progestin (medroxyprogesterone acetate 2.5 mg/day) or placebo. IOP was measured 5 years after randomization. Adjusted linear regression models were used to assess the association between hormone therapy and IOP.
resultsThe WHISE included 1668 women in the estrogen-alone trial (aged 63-86, mean 72 years) and 2679 women in the estrogen-plus-progestin trial (aged 63-87, mean 72 years). In multivariate analyses, compared to placebo treatment, treatment with estrogen alone was associated with a 0.5 mm Hg reduction of the IOP in the right eye (95% CI: -0.8, -0.1, P = .005) and a 0.6 mm Hg (95% CI: -0.9, -0.3, P < .001) reduction of the IOP in the left eye. In the estrogen-plus-progestin trial, there was no significant difference in IOP between the treatment and placebo groups (P = .30 right eye and P = .43 left eye).
conclusionsThis study represents an IOP analysis in the largest hormone trial available. Estrogen-alone therapy in postmenopausal women is associated with a small but significant IOP reduction of 0.5 mm Hg. The clinical significance of this small decrease remains to be determined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.